

Operational Update

Urgent C19RM Reinvestments

20 July 2022

Dear colleagues,

Due to the changing nature of the COVID-19 pandemic and contributing factors, the Global Fund will be supporting implementing countries to urgently reinvest COVID-19 Response Mechanism (C19RM) funds, where the initial intent of these investments no longer responds to current and projected national needs and priorities.

The reinvestment process is also an unprecedented opportunity to align C19RM funding with the priorities of the 2023-2025 funding cycle, particularly strengthening health and community systems and preparedness for future pandemics.

For implementing countries to be able to use C19RM funds by the 31 December 2023 deadline, **reinvestment decisions need to be approved by Country Teams by 31 August 2022** to allow for health products orders lead-times and complete key implementation milestones.

During the reinvestment dialogue, implementing countries will be required to **identify new and/or update their unfunded demand** to be ready for a C19RM Portfolio Optimization wave in September 2022. Portfolio Optimization is a Global Fund financing process that swiftly provides countries with additional funds to enable the scale-up of existing interventions within the scope of C19RM.

To streamline reinvestment efforts with C19RM Portfolio Optimization, **registration of unfunded demand should be done by 2 September 2022**.

Information sessions for CCMs and PRs will take place on 25 and 26 July, and 4 and 5 August. Links to sessions can be found below.

Best regards,

The Global Fund

C19RM Reinvestments Information Sessions

Information sessions for CCMs and PRs will take place as follows:

- Monday, 25 July from 10:30-12:00 CEST in English – [link to join this session](#).
- Tuesday, 26 July from 10:30-12:30 CEST in French – [link to join this session](#).
- Thursday, 4 August from 10:30-12:00 CEST in English – [link to join this session](#).
- Friday, 5 August from 10:30-12:00 CEST in French – [link to join this session](#).

Recordings and presentations will be available after the sessions.

C19RM Reinvestments Updated Guidance

Purpose

To maximize the impact of C19RM funds through supporting countries to be more ambitious in adapting their C19RM interventions to evolving national responses and needs, country implementation experience, and the opportunities within C19RM's scope, especially the areas outlined in this document.

The document links to details on lead-times, costs and procurement considerations to inform re-invest decision making.

Countries are encouraged to concentrate reinvestment planning and C19RM Portfolio Optimization on strategically selected interventions that allow greater scale, instead of selecting a higher number of smaller interventions. The greater scale approach allows for more efficient investments and successful program implementation.

Key Priority Areas

When the COVID-19 Response Mechanism was created in 2020, the Global Fund Board set three areas of investments for eligible funding: (1) COVID-19 response; (2) COVID-19-related adaptation of programs to fight HIV, TB and malaria; and (3) strengthening health and community systems. Within these three C19RM areas of investment, high value reinvestment opportunities have been identified based on country feedback and emerging best practices:

1. Adapt COVID-19 responses and interventions to current context

- Re-quantify COVID-19 diagnostics and PPE. This can make C19RM funds available for immediate reinvestment in other areas.
- Infection prevention and control.
- Medical oxygen.
- Novel therapeutics, test and treat and self-testing.

2. Enable HIV, tuberculosis and malaria program integration and mitigation

- Cover additional costs of procurement and supply chain management (PSM) of health products.
- Bi-directional screening - TB/COVID-19 integration.
- HIV, TB and malaria commodities remain outside C19RM scope (except TB cartridges as part of an integrated response).

3. Enhance systems and infrastructure to boost responses

- Pandemic preparedness.
- Laboratory system strengthening.
- Respiratory disease surveillance, data systems and response.
- Community health/community health workers.
- Supply chain and waste management.
- Bring forward RSSH plans.

The [Annex 6: Guidance for C19RM Reinvestment Planning](#) provides technical and programmatic orientated materials.

Supply Operations Guidance

Lead times, pricing and cost guidance for health products

Updated resources are available on the following links:

- **Category and Product-level Procurement and Delivery Planning Guide** ([English](#) | [French](#)). This document lays out indicative lead times for planning purposes for key health products for the Global Fund's Pooled Procurement Mechanism (PPM)
- [Stop TB Partnership's Global Drug Facility](#). This document lays out indicative lead times for planning purposes for TB products procured via the Stop TB Partnership's Global Drug Facility (STBP/GDF).

Detailed information on COVID-19 product cost references prices are available for [diagnostics](#), [PPE](#), [O2](#), [health equipment](#) (including sequencers, X-ray, incinerators and other hospital and laboratory equipment), [treatment](#) and [non-health products](#) (vehicles, computers).

Key Dates

- **By 31 August 2022:** C19RM reinvestment decisions approved by Global Fund Country Teams.
- **From September 2022:** C19RM Portfolio Optimization wave.
- **By 2 September 2022:** Registration of C19RM unfunded demand.
- **30 September 2022:** Detailed Budgets updated in GOS to reflect material revisions (only for grants that have no unfunded demand registered).
- **End of September:** Requisitions for PSA plants to be procured via Wambo.org.
- **31 October (or earlier if Board Approval is not required):** Countries are notified of Portfolio Optimization decisions.